A Phase 4, Randomized, Open Label, Parallel Group, Multicenter Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin or Rapid Acting Insulin in Patients With Type 2 Diabetes.

Trial Profile

A Phase 4, Randomized, Open Label, Parallel Group, Multicenter Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin or Rapid Acting Insulin in Patients With Type 2 Diabetes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs Pramlintide (Primary) ; Insulin aspart; Insulin detemir; Insulin glargine; Insulin glulisine; Insulin lispro; Insulins
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INSTEAD
  • Sponsors Amylin Pharmaceuticals
  • Most Recent Events

    • 03 Mar 2010 Treatment satisfaction and quality-of-life effects published in Current Medical Research and Opinion.
    • 29 Sep 2009 Results have been presented at EASD 2009.
    • 01 Sep 2009 Results published in Diabetes Care.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top